2017年中国临床肿瘤学会年会胰腺癌研究进展解析  

Analysis of the advances in pancreatic cancer research from 2017 annual meeting of Chinese Society of Clinical Oncology

作　　者：许文彦 徐近 虞先濬 

机构地区：[1]复旦大学附属肿瘤医院胰腺外科复旦大学胰腺肿瘤研究所上海市胰腺肿瘤研究所复旦大学上海医学院肿瘤学系,200032

出　　处：《中华消化外科杂志》2017年第11期1105-1108,共4页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金杰出青年项目（81625016）;国家自然科学基金面上项目（81372651）;国家自然科学基金青年项目（81502031）

摘　　要：胰腺癌是消化系统恶性程度极高的肿瘤，病情进展快，预后极差。近年来，胰腺癌发病率亦明显升高。随着对胰腺癌发生、发展机制研究的不断深入，研究者对疾病本身有了更加清晰的认识，也为基础到临床的转化应用提供了线索。第20届全国临床肿瘤学大会暨2017年中国临床肿瘤学会（CSCO）年会于2017年9月26—30日在厦门举行。笔者团队就本次会议中胰腺癌外科手术治疗、化疗、放疗、分子靶向治疗、免疫治疗等方面的研究进展作一整理和解析，以期为胰腺癌诊断与治疗方案的优化提供新思路。Pancreatic cancer is a highly malignant, fa^t progressive digestive system neoplasm with poor prognosis, and the incidence has increased significantly in recent years. With deepening of the molecular mechanism of pancreatic cancer, researchers indeed have a clearer understanding of the disease, which provides clues for translation of basic research into clinical practice. The 2017 annual meeting of the Chinese Society of Clinical Oncology （CSCO） was held in Xiamen on September 26th to 30th. In this paper, authors selected and reviewed advances in pancreatic cancer research on surgical treatment, chemotherapy, radiotherapy, targeted therapy and immunotherapy on pancreatic cancer from 2017 CSCO, in order to provide new clues for optimization of diagnosis and treatment of pancreatic cancer.

关 键 词：胰腺肿瘤 外科手术 化疗 放疗 靶向治疗 免疫治疗 

分 类 号：R735.9[医药卫生—肿瘤]